Long‐term changes in bone mineral density and predicted fracture risk in patients receiving androgen‐deprivation therapy for prostate cancer, with stratification of treatment based on presenting values
Authors:
- 21 August 2009
- journal article
- Published by Wiley in BJU International
- Vol. 104 (6) , 800-805
Abstract
OBJECTIVE: To study the long‐term effects of androgen‐deprivation therapy (ADT) using luteinizing hormone‐releasing hormone (LHRH) agonists or antiandrogen therapy with bicalutamide on bone mineral density (BMD) of selected groups of patients with newly diagnosed advanced prostate cancer, stratified by BMD at presentation and to predict alterations in fracture risk. PATIENTS AND METHODS: In all, 618 men with a mean (sd, range) age of 73 (7.1, 49–94) years, initiating ADT for prostate cancer were prospectively recruited and followed from October 1999 to January 2007. BMD was measured by forearm dual‐energy X‐ray absorptiometry (DEXA) before ADT and repeated annually. Patients with osteoporosis (T‐score ≤−2.5) were commenced on bicalutamide; patients with osteopenia (T‐score between −1.0 and −2.5) and normal BMD (T‐score > −1.0) were commenced on an LHRH agonist. Patients with osteopenia and osteoporosis received calcium and vitamin D supplements. RESULTS: Over 7 years, 1690 DEXA scans were performed. In all, 41% of patients with newly diagnosed prostate cancer were osteoporotic, 39% were osteopenic and 20% had normal BMD. In the normal group, treated with an LHRH agonist, there were significant decreases in BMD (1 year 1.2%; 2 year 3.7%; 3 year 6.5%; 4 year 8.9%; 5 year 9.9%; 6 year 12.7%), which also occurred in the patients with osteopenia with 60% developing osteoporosis after 2 years (1 year 1.8%; 2 year 5.1%; 3 year 8.0%; 4 year 8.2%; 5 year 11.5%; 6 year 14.1%). By contrast, the osteoporotic group maintained BMD (1 year 0.5%; 2 year 0%; 3 year +1.2%; 4 year 0.5%; 5 year 1.7%; 6 year 2.2%). CONCLUSION: Patients treated with an LHRH agonist have significant and sustained decreases in BMD, whereas bicalutamide maintains BMD. We advocate routine assessment of BMD before ADT, with surveillance thereafter.Keywords
This publication has 25 references indexed in Scilit:
- Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body CompositionJournal of Clinical Oncology, 2004
- BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCERJournal of Urology, 2004
- Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2001
- PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCERJournal of Urology, 2000
- Bone Density and Fracture Risk in MenJournal of Bone and Mineral Research, 1998
- Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam StudyJournal of Bone and Mineral Research, 1998
- A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate CancerEuropean Urology, 1998
- Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trialBritish Journal of Urology, 1997
- Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinomaCancer, 1997
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ, 1996